

INVITATION

The German-Israeli Cooperation in Cancer Research was founded in 1976 and belongs to the longest lasting scientific cooperations of both countries. To date, more than 160 joint projects have been funded. Importantly, the cooperation has also strongly fostered friendship between scientists from Germany and Israel and other involved partners (www.dkfz.de/israel).

The aim of the German-Israeli Cancer Research School established in 2008 is to provide a platform for intensive interaction between students, young researchers and principal investigators from both nationalities on essential and emerging areas of cancer research.

The 8th German-Israeli Cancer Research School in November 2016 is dedicated to Cancer Immunotherapy. On this occasion, we will review the spectacular recent progress in this area with respect to the clinical application of – for instance – checkpoint inhibitors and adoptive T cell therapies, discuss the latest insights in the regulation of immunity in health and disease, and – most importantly – aim at identifying new opportunities in the pre-clinical and clinical tumor immunology research.

The meeting offers an exciting program of seminars by 16 cancer immunotherapy/tumor immunology experts, 8 from Israel and 8 from Germany. This year's keynote lecture will be delivered by Prof. Zelig Eshhar, who has recently received the Israel Prize for his contributions to the field.

An important aspect of this year's program is that all participating PhD students will present their own project at prime time during the meeting. On each morning between 10.30 and noon, 8 PhD students will give 10-minute flash-talks, after which they can display their work in further details during the subsequent poster session. The best posters will be awarded.

Since we will be staying close to Jerusalem, we will – of course – have an excursion to this famous historic city. Last but not least, we will have a special lecture by Prof. Amotz Zahavi, a famous Israeli evolutionary biologist who brought forward the 'Handicap Principle', an intensely debated theory aimed at explaining why animals – and humans – invest so much energy in physical and behavioral displays.

Peter Angel

Hagit Schwimmer

ORGANIZERS

Scientific Program Committee

DKFZ: Prof. Dr. Rienk Offringa

Israel: Prof. Dr. Roni Apte and Prof. Dr. Varda Rotter

German-Israeli Cooperation in Cancer Research

DKFZ: Prof. Dr. Peter Angel

Israel: Dr. Hagit Schwimmer

Administrative Coordinator

Susanne Schunk

Contact Address DKFZ

Susanne Schunk
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
D-69120 Heidelberg, Germany
phone: +49 6221 42-4499
e-mail: susanne.schunk@dkfz.de

Contact Address MOST

Shani Edri / Aviel Abraham
Ministry of Science, Technology and Space
P. O. Box 49100
Jerusalem 91490, Israel
phone: +972 2 5411850
e-mail: shanie@most.gov.il / avielab@most.gov.il

Venue


Location near Jerusalem, Israel (TBD)

Participation

Participation is restricted to 24 students and junior postdocs (12 from DKFZ and 12 from Israel) who will be selected on basis of CV and abstract by the Joint Scientific Committee.

Application

For application see www.dkfz.de/en/israel/school-2016/school-2016.html. Please, send application form together with poster abstract to DKFZ-School@most.gov.il by August 5th, 2016. There will be no registration fee; accommodation, breakfast and dinner are covered by the organizers.



8th German-Israeli Cancer Research School
CANCER IMMUNOTHERAPY

Location near Jerusalem, Israel (TBD)
November 20 – 24, 2016

Sunday, November 20th, 2016

Arrival in the afternoon

19:00 Welcome Dinner

Monday, November 21th, 2016

- 08:30 **Ofer Mandelboim**
Recognition of bacteria by NK cells
- 09:15 **Angel Porgador**
Natural killer immunity and cancer immunome
- 10:00 Break
- 10:30 Flash talks by PhD students and junior postdocs
- 12:00 PhD students and junior postdocs poster session and lunch buffet
- 13:30 **Thomas Woelfel**
Analyses of the anti-tumor T cell repertoire in melanoma patients
- 14:15 **Gerald Willimsky**
Identification of tumor-specific rejection antigens for TCR gene therapy
- 15:00 **Michael Platten**
Immunotherapy of brain tumors
- 15:45 Break
- 16:15 **Barbara Seliger**
Many mechanisms of tumors leading to target-less T cells
- 17:00 **Gal Markel**
Immune resistance mechanisms in melanoma
- 17:45 Happy hour
- 19:00 Dinner, followed by a social activity

Tuesday, November 22th, 2016

- 08:30 **Ron Apte**
Microenvironment IL-1 is a major determinant of the balance between immunity and inflammation at tumor sites
- 09:15 **Vigo Heissmeyer**
Roquin-deficient T cells create a tumor-inducing micro-milieu in the pancreas
- 10:00 Break
- 10:30 Flash talks by PhD students and junior postdocs
- 12:00 PhD students and junior postdocs poster session and lunch buffet
- 13:30 Afternoon excursion to Jerusalem
- 19:00 Dinner
- 20:00 **SPECIAL LECTURE:**
Amotz Zahavi
The Handicap Principle: a missing piece of Darwin's puzzle

Wednesday, November 23th, 2016

- 08:30 **Dirk Busch**
Adoptive T cell therapy: from single cells to immunity
- 09:15 **Michal Lotem**
Co-stimulation of CD8 T cells, beyond APC: lymphocyte interactions
- 10:00 Break

Wednesday, November 23th, 2016

- 10:30 Flash talks by PhD students and junior postdocs
- 12:00 PhD students and junior postdocs poster session and lunch buffet
- 13:30 **KEYNOTE LECTURE:**
Zelig Eshhar
The chimeric antigen receptor T cells: from the mouse Cage to the patient health
- 14:15 **Yoram Reitter**
Engineering immune molecules and cells for novel cancer immunotherapy
- 15:00 **Michael Bachmann**
Retargeting of immune cells to tumor cells
- 15:45 Break
- 16:15 **Jacob Schachter**
Immunotherapy – the new platform for the treatment of cancer
- 17:00 **Rienk Offringa**
Immunotherapy of pancreatic cancer in the neo-adjuvant and adjuvant setting
- 17:45 Happy hour
- 19:00 Closing dinner party